12:00 AM
 | 
Jun 18, 2001
 |  BioCentury  |  Strategy

Looking for more downstream deals

Celera Genomics Group has taken a step toward life in the post-genomics space with its planned purchase of Axys Pharmaceuticals Inc., which will provide CRA with biology and chemistry capabilities needed to build a fully integrated drug discovery business system. And CRA is looking for more deals to move further downstream.

CRA has already started to develop its own vaccine and antibody-based therapeutics, but had no small molecule discovery capability before announcing the planned Axys acquisiton...

Read the full 361 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >